Table 1.
Prevalence of TAMs and M184V in patients with paired genotypes (n = 36) at weeks 48 and 96, by treatment arm
| ABC (n = 22) |
NVP (n = 14) |
|||||||
|---|---|---|---|---|---|---|---|---|
| week 48 |
week 96 |
week 48 |
week 96 |
|||||
| n | % | n | % | n | % | n | % | |
| Mutation | ||||||||
| 184V | 22 | 100 | 22 | 100 | 12 | 86 | 13 | 93 |
| 41L | 2 | 9 | 8 | 36 | 1 | 7 | 4 | 29 |
| 67N | 9 | 41 | 15 | 68 | 5 | 36 | 6 | 43 |
| 70R | 9 | 41 | 14 | 64 | 2 | 14 | 4 | 29 |
| 210W | 0 | 0 | 7 | 32 | 1 | 7 | 5 | 36 |
| 215F | 3 | 14 | 7 | 32 | 0 | 0 | 5 | 36 |
| 215Y | 3 | 14 | 9 | 41 | 2 | 14 | 5 | 36 |
| 219QE | 4 | 18 | 11 | 50 | 1 | 7 | 4 | 29 |
| No. of TAMs | ||||||||
| 0 | 9 | 41 | 3 | 14 | 8 | 57 | 3 | 21 |
| 1 | 2 | 9 | 1 | 5 | 2 | 14 | 1 | 7 |
| 2 | 6 | 27 | 2 | 9 | 2 | 14 | 3 | 21 |
| 3 | 4 | 18 | 4 | 18 | 2 | 14 | 2 | 14 |
| ≥4 | 1 | 5 | 12 | 55 | 0 | 0 | 5 | 36 |
ABC, abacavir; NVP, nevirapine.